Skip to main content

Table 6 Summary statistics of data used in models reported in Table 7, by procurement type, 2010–2014

From: How well does Malaysia achieve value for money in public sector purchasing of medicines? Evidence from medicines procurement prices from 2010 to 2014

VariablesProcurement Type
APPL
(n = 593)
National tender
(n = 150)
Direct Purchase
(n = 522)
Number of medicines formulations, (%)
 201014.519.316.3
 201127.523.318.2
 201219.122.022.2
 201317.718.021.5
 201421.217.321.8
Medicine source and category, (%)
 Local generic70.232.036.4
 Imported generic20.218.030.3
 Originator9.650.033.3
Route of administration, (%)
 Injectables30.030.715.5
 Oral preparation61.560.662.8
 Other preparations8.58.721.7
Median price ratioa (Interquartile range)
 20101.58 (0.92–3.03)2.08 (1.04–5.24)2.77 (1.59–5.64)
 20111.69 (0.98–5.89)1.98 (0.97–5.89)2.22 (1.41–5.00)
 20121.61 (0.84–3.81)1.24 (0.56–5.57)2.16 (1.26–4.65)
 20131.80 (0.83–3.84)1.52 (0.94–6.12)1.75 (1.14–4.08)
 20141.50 (0.81–3.98)1.35 (0.60–4.06)1.69 (1.11–4.19)
Total quantity (‘000,000 DDDs), Mean (SD)9.1 (33.5)3.9 (16.7)0.2 (0.6)
Total expenditure (‘000,000 MYR), Mean (SD)2.0 (5.4)1.6 (3.2)0.1 (0.3)
  1. a Unweighted 50th percentile price ratio relative to MSH international reference prices of all products by procurement type for each year